Item 5. Other Information
Item 5. Other Information
None.
70
Item 6. Exhibits
The documents listed in the Exhibit List, which follows below, are incorporated by reference or are filed with this quarterly report on Form 10-Q, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).
EXHIBIT LIST
Exhibit
Number Description Incorporated
by Reference
From Form Incorporated
by Reference
From Exhibit
Number Date Filed
3.1 Eighth Amended and Restated Certificate of Incorporation filed on February 15, 2011.
10-K 3.1 3/28/2011
3.2 Amended and Restated Bylaws of Standard BioTools Inc.
S-8 4.8 4/1/2022
3.3 Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation.
S-8 4.3 4/1/2022
3.4 Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock .
8-K 3.1 11/22/2016
3.5 Certificate of Elimination of Series A Participating Preferred Stock.
8-K 3.1 8/2/2017
3.6 Certificate of Designations of Rights, Preferences and Privileges of Series B-1 Convertible Preferred Stock.
8-K 3.6 4/5/2022
3.7 Certificate of Designations of Rights, Preferences and Privileges of Series B-2 Convertible Preferred Stock.
8-K 3.7 4/5/2022
10.1 Series B-1 Loan Agreement, dated as of January 23, 2022, by and among Fluidigm Corporation, Casdin Partners Master Fund, L.P., and Casdin Private Growth Equity Fund II, L.P.
8-K/A 10.1 2/11/2022
10.2 Series B-2 Loan Agreement, dated as of January 23, 2022, by and among Fluidigm Corporation, Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP.
8-K 10.2 1/24/2022
10.3 Series B-1 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, by and among Fluidigm Corporation, Casdin Private Growth Equity Fund II, L.P., and Casdin Partners Master Fund, L.P.
DEF 14A Anx. B 2/24/2022
10.4 Series B-2 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, by and among Fluidigm Corporation, Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP.
DEF 14A Anx. C 2/24/2022
10.5 Registration Rights Agreement, dated as of January 23, 2022, by and between Fluidigm Corporation, Casdin Private Growth Equity Fund II, L.P., Casdin Partners Master Fund, L.P., Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP.
8-K 10.5 1/24/2022
10.6+ Stephen Christopher Linthwaite Transition Agreement and Release.
8-K 10.6 1/24/2022
10.7+ Michael Egholm Offer Letter .
8-K 10.7 1/24/2022
10.8 Indemnification Agreement, dated January 23, 2022, by and between the Company and Michael Egholm.
8-K 10.8 1/24/2022
10.9+ Hanjoon Alex Kim Offer Letter .
8-K 10.9 1/24/2022
10.10+ Standard BioTools 2022 Inducement Equity Incentive Plan .
S-8 4.9 4/1/2022
10.11+ Form of Notice of Stock Option Grant and Stock Option Agreement under the 2022 Inducement Equity Incentive Plan .
S-8 99.1 4/1/2022
10.12+ Form of Notice of Restricted Stock Unit Grant and Restricted Stock Unit Agreement under the 2022 Inducement Equity Incentive Plan .
S-8 99.2 4/1/2022
10.13+ Form of Retention Letter.
8-K 10.10 1/24/2022
10.14 Default Waiver and Consent to Loan and Security Agreement, dated March 4, 2022, between the Company and Silicon Valley Bank.
10-K 10.19F 3/8/2022
10.15 Letter Agreement dated March 25, 2022 .
8-K 10.1 3/28/2022
10.16 Support Agreement, dated March 29, 2022, by and among Fluidigm Corporation and Caligan Partners LP and certain of its affiliates .
8-K 10.1 3/29/2022
71
Exhibit
Number Description Incorporated
by Reference
From Form Incorporated
by Reference
From Exhibit
Number Date Filed
31.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of Chief Executive Officer.
Filed herewith
31.2 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of Chief Financial Officer.
Filed herewith
32.1 (1)
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of Chief Executive Officer.
Filed herewith
32.2 (1)
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of Chief Financial Officer.
Filed herewith
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. Filed herewith
101.SCH XBRL Taxonomy Extension Schema Document Filed herewith
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document Filed herewith
101.DEF XBRL Taxonomy Extension Definition Linkbase Document Filed herewith
101.LAB XBRL Taxonomy Extension Label Document Filed herewith
101.PRE XBRL Taxonomy Extension Presentation Document Filed herewith
* Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).
+ Indicates management contract or compensatory plan, contract, or arrangement.
(1) In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.
72
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
STANDARD BIOTOOLS INC.
Dated: May 9, 2022 By: /s/ Michael Egholm
Michael Egholm
Chief Executive Officer and President
Dated: May 9, 2022 By: /s/ Vikram Jog
Vikram Jog
Chief Financial Officer
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.